Enjoy complimentary customisation on priority with our Enterprise License!
About depression drugs
According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration. Depression can be roughly categorized into six different types. An individual with severe depression can have suicidal thoughts and behaviors. According to a 2012 estimate by the WHO, about 3,000 suicides take place each day, resulting in more than a million deaths each year. Depression can be recurrent and can be severely debilitating. Patients with mild depression can be treated with medications, but in cases of moderate or severe depression, the patient needs both medication and professional psychotherapy in the form of counseling. According to a 2008 report by the WHO, depression affects men and women equally, but women are more likely to be affected by depression than men. According to the CDC, depression can lead to many adverse behaviors in an individual such as alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, in the US, one in every 10 individuals is affected by depression. According to the NIMH in the US, major depressive disorder is one of the most debilitating disorders in the US and affects about 14.80 million adults aged 18 years and above.
Technavio's analysts forecast the global depression drugs market to grow at a CAGR of 5.25% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global depression drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of depression. The global depression drugs market is segmented based on the mechanism of action of the drugs used to treat depression, as mentioned below:
• Tricyclic antidepressants
• Serotonin-norepinephrine reuptake inhibitors
• Selective serotonin reuptake inhibitors
• Monoamine oxidase inhibitors
• Others
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market overview
03.2 Product offerings
04. Product Profiles
04.1.1 Celexa
04.1.2 Fetzima
04.1.3 Lexapro
04.1.4 Viibryd
04.1.5 Cymbalta
04.1.6 Prozac
04.1.7 Symbyax
04.1.8 Paxil
04.1.9 Wellbutrin
04.1.10 Abilify
04.1.11 Effexor
04.1.12 Pristiq
04.1.13 Zoloft
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disorder Overview
07.1 Types of depression
07.1.1 Major depressive disorder
07.1.2 Persistent depressive disorder
07.1.3 Psychotic depression
07.1.4 Postpartum depression
07.1.5 Seasonal affective disorder
07.1.6 Bipolar disorder
07.2 Etiology
07.3 Epidemiology
07.3.1 Bipolar disorder among adults
07.3.2 Dysthymic disorder among adults
07.3.3 Major depression among adults
07.3.4 Major depression among adolescents
07.4 Treatment and management
07.5 Economic burden
08. Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 Depression drugs market in US 2014-2019
08.3.1 Market size and forecast
08.4 Five forces analysis
09. Market Segmentation by Mechanism of Action
10. Geographical Segmentation
10.1 Segmentation of global depression drugs market by geography 2014
11. Pipeline Portfolio
11.1 Key information on late-stage pipeline molecules
11.1.1 Brexpiprazole
11.1.2 ALKS 5461
11.1.3 Cariprazine
11.1.4 TGFK07AD
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive scenario
19.1.1 Key news
19.1.2 Mergers and acquisitions
19.2 Market share analysis 2014
19.2.1 Competitive assessment of top drugs used for treating depression
19.2.2 Bristol-Myers Squibb
19.2.3 Eli Lilly
19.2.4 Pfizer
19.2.5 GlaxoSmithKline
19.2.6 Actavis
19.3 Other and future prominent vendors
20. Key Vendor Analysis
20.1 Actavis
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Geographical segmentation by Sales 2013
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 Bristol-Myers Squibb
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Key Product Offerings
20.2.4 Revenue by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 Eli Lilly
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue
20.3.4 Sales by Geography
20.3.5 Business Strategy
20.3.6 Key Information
20.3.7 SWOT Analysis
20.4 GlaxoSmithKline
20.4.1 Key facts
20.4.2 Business overview
20.4.3 Business segmentation by revenue 2014
20.4.4 Business segmentation by revenue 2013 and 2014
20.4.5 Geographical segmentation by revenue 2014
20.4.6 Business strategy
20.4.7 Recent developments
20.4.8 SWOT analysis
20.5 Pfizer
20.5.1 Key facts
20.5.2 Business overview
20.5.3 Business segmentation by revenue 2014
20.5.4 Business segmentation by revenue 2013 and 2014
20.5.5 Geographical segmentation by revenue 2014
20.5.6 Business strategy
20.5.7 Key developments
20.5.8 SWOT analysis
21. Other Reports in this Series
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.